Please assess the completion status of the following clinical trial:

Trial Title: Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
-INCLUSION CRITERIA~1. Histologically confirmed colorectal adenocarcinoma with metastatic disease confined to the liver, or limited extrahepatic intra-abdominal disease Note: limited sites of disease include:~   * porta hepatis lymph node metastases~  * pelvic lymph node metastases (internal iliac, external iliac or obturator)~2. Hepatic and intra-abdominal metastases must be measurable by computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan~3. Liver disease must be amenable to gross total resection (R0/R1) with adequate functional liver remnant which requires preservation of at least 2 contiguous hepatic segments with adequate inflow, outflow, and biliary drainage with a functional liver remnant (FLR) volume of more than 20% (for healthy liver)~4. Greater than or equal to 18 years of age.~5. Must be able to understand and sign the Informed Consent Documentation.~6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 2.~7. Life expectancy of greater than six months.~8. Patients of both genders must be willing to practice birth control during and for one week after taking sulindac/placebo.~9. Hematology:~   * Absolute neutrophil count greater than 1500/mm\^3 without the support of Filgrastim.~  * Platelet count greater than 75,000/mm\^3.~  * Hemoglobin greater than 8.0 g/dl.~10. Chemistry:~    * Serum creatinine less than or equal to 1.5 mg/dl unless the measured creatinine clearance is greater than 60mL/min/1.73m\^2.~   * Total bilirubin less than or equal to 2 mg/dl, except for patients with diagnosis of Gilberts disease or hepatic pedicle obstruction then total bilirubin must be less than or equal to 5 mg/dl.~11. International normalized ratio (INR) less than or equal to 1.8.~INCLUSION CRITERIA for NORMAL VOLUNTEERS~* Age greater than 18~* Able to read and understand the informed consent~* No self-reported co morbidities of history of cancer~EXCLUSION CRITERIA~1. Women of child-bearing potential who are pregnant or breast feeding because of the potentially dangerous effects of the chemotherapy on the fetus or infant.~2. Active systemic infections, coagulation disorders or other major medical illnesses precluding major surgery.~3. Patients receiving warfarin anticoagulation, who cannot be transferred to other agents, such as low molecular weight heparins, anti-factor Xa (anti-Xa) agents, etc.~4. Active bleeding disorders~5. Patients with uncontrolled hypertension (would suggest: systolic blood pressure (SBP)\> 155, diastolic blood pressure (DBP)\> 90), unstable coronary disease (unstable angina, evidence of congestive heart failure (CHF), or myocardial infarction (MI) within 6-12 months of study)~6. Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies or with evidence of moderate to severe ascites.~7. Prior history of gastrointestinal (GI) bleeding unrelated to a cancer diagnosis~   Note: Patients who have a normal upper and lower endoscopy may be enrolled at the discretion of the principal investigator (PI).~8. Renal insufficiency Discretion of principle investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sulindac (Type: ACTIVE_COMPARATOR): one tablet twice daily
- Placebo (Type: PLACEBO_COMPARATOR): one tablet twice daily
- Normal Volunteers (or control group) (Type: OTHER): Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.

Based on this trial design, predict the completion outcome and termination type (if applicable).